Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile
| Autor: | Vianney Tuloup, Mathilde France, Romain Garreau, Nathalie Bleyzac, Laurent Bourguignon, Michel Tod, Sylvain Goutelle |
|---|---|
| Přispěvatelé: | Hospices Civils de Lyon (HCL), Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Rifabutin
MESH: Drug Interactions MESH: Pharmaceutical Preparations Drug-drug interaction Rifamycins Pharmacology Staphylococcal infections MESH: Rifamycins Pharmacokinetics parasitic diseases medicine polycyclic compounds Drug Interactions Pharmacology (medical) heterocyclic compounds Rifampicin biology business.industry Cytochrome P450 biochemical phenomena metabolism and nutrition medicine.disease bacterial infections and mycoses MESH: Rifampin Infectious Diseases [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology Pharmaceutical Preparations MESH: Rifabutin biology.protein [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology Rifampin business medicine.drug |
| Zdroj: | Antimicrobial Agents and Chemotherapy Antimicrobial Agents and Chemotherapy, 2021, 65 (9), pp.e0104321. ⟨10.1128/AAC.01043-21⟩ Antimicrob Agents Chemother |
| ISSN: | 0066-4804 1098-6596 |
| DOI: | 10.1128/AAC.01043-21⟩ |
| Popis: | International audience; Rifamycins are widely used for treating mycobacterial and staphylococcal infections. Drug-drug interactions (DDI) caused by rifampicin (RIF) are a major issue. We used a model-based approach to predict the magnitude of DDI with RIF and rifabutin (RBT) for 217 cytochrome P450 (CYP) substrates. On average, DDI caused by low-dose RIF were twice as potent as those caused by RBT. Contrary to RIF, RBT appears unlikely to cause severe DDI, even with sensitive CYP substrates. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|